Fortress Biotech Inc 9.375% Series A Cumulativ (FBIOP) Stock Price, Quote & News

Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-n...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Website: www.fortressbiotech.com

Address:

1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States

makrodimutross Oct. 24 at 4:52 PM

$FBIO $FBIOP this is excellent news for Helocyte. And P2 data is due any moment now from the 30 / 60 1:2 HIV study. 96 week follow up after complete enrolment was several weeks ago now.

0 · Reply

thesaltier1 Oct. 24 at 12:57 PM

$FBIOP this is your gift today, derm released positive news, fbio is moving but fbiop is not, this is a disconnect. remember that as derm sales increase then cash flow increases and $FBIOP should directly benefit more than fbio....as this increases chances of dividend being restored

0 · Reply

Sawnchey Oct. 23 at 4:48 PM

$FBIO $FBIOP A miss for Moderna in the CMV vaccine space. This puts all the more significance on the upcoming Triplex readouts. https://endpoints.news/modernas-cmv-vaccine-fails-phase-3-study-company-to-halt-most-development/?u=4562bd47-74cd-4c9f-9e0c-123b64557ebe&s=email&c=79153abc-da9759b9-4e537c38&utm_medium=email&utm_campaign=2316%20-%20Is%20neurology%20the%20hottest%20target%20for%20dealmaking%20Plus%20Mikael%20Dolstens%20new%20startup%20Basic&utm_content=2316%20-%20Is%20neurology%20the%20hottest%20target%20for%20dealmaking%20Plus%20Mikael%20Dolstens%20new%20startup%20Basic+CID_d55d83919f099059ced9c189f68f53e6&utm_source=ENDPOINTS%20emails&utm_term=Modernas%20CMV%20vaccine%20fails%20Phase%203%20study%20ending%20long-shot%20prevention%20effort

0 · Reply

thesaltier1 Oct. 23 at 4:24 PM

$FBIOP every month that goes by is another accumulated dividend, but every month that goes by also makes me feel like I am making a big mistake....6 months ago I thought this was a steal at $6 a share....and here we are again

0 · Reply

Sawnchey Oct. 11 at 1:06 PM

$FBIOP I would actually be quite happy to see a further dip here, I love buying below 7 dollars, it feels like very good value when compared against the cumulated undeclared dividends.

2 · Reply

makrodimutross Oct. 10 at 7:00 PM

$FBIO $FBIOP This chart is fundamentally retarded, but it offers a glimpse of how massive the current arbitrage opportunity truly is with Fortress preferred stock. The market made sense of the capital structure for several months. Now? Apparently the future prospects for the company are still rosy on average, but the debt securities are questionable in relation to these future prospects. Make it make sense.

1 · Reply

Kconn52 Oct. 5 at 3:48 PM

$FBIOP I have been bidding my time before expressing my opinion but I am surprised that LR and MW were caught unaware on this CMC hiccup. Seems like poor oversight and weak management. Combined with the poor results on some other projects, it has seriously damaged their standing as leaders. Beyond all else, this concerns me greatly.

1 · Reply

makrodimutross Oct. 4 at 8:52 PM

$FBIO $FBIOP My rough prediction for Q3 wrap now: Fortress / consolidated (in millions), ultra basic Revs: 18 COGS: 6 Dep./Am.: 1 R+D: 1.2 (Saving 6.9m from Q2 CKPT expenses) SG+A: 18.9 (Saving 19.9m from Q2 CKPT expenses) Interest Exp.: 2.5 Earnings at -11.6m Fortress looks like they will be burning approximately 10m per Q... even as they ramp EMROSI, the SG+A will also increase through DERM to a ceiling value TBD. Oaktree note has a 30 month interest only expense, From July 2024. That means in January 2027 they will need to begin payback of principal. Currently they've only drawn 35m, but can access another 15m if they're on their best behavior. There seems to be a way through this without another S-3 in the next 12 months. If my prediction is correct, FBIO will have around 65m in cash at this time, and approximately 6 quarters (1.5 years) to right the ship... and most certainly by January 2027. Wild card is the FDA curtailment, and their non-acceptance of "New NDA's" at this time.

3 · Reply

Zelltable Oct. 4 at 7:08 PM

$FBIO $FBIOP My cousin Zellchair may be questioning his entire investment and has been fickle with both preferred and common, but I am all in, baby!!! Even if waiting for preferred dividends to resume feels like waiting for Santa Clause, I don’t care! My cousin may be wasting time with his indecisiveness on these tickers, but my answer is plain and simple: FBIO and FBIOP ride or die!!

2 · Reply

Chaka1647 Oct. 2 at 3:55 PM

If the commons stays elevated, can def see a raise to get $FBIOP paid off Interesting times

2 · Reply

Market Cap	N/A
Revenue (ttm)	84.51M
Net Income (ttm)	-60.64M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	304
Avg Vol	18,892
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	79%
Beta	N/A
Analysts	Strong Buy
Price Target	N/A